BioInvent International AB 2022 AR2
The report highlights BioInvent's progress in 2022, during which the company expanded its clinical pipeline to five projects in ongoing clinical development. Key achievements included a new exclusive option and license agreement with Exelixis, a milestone payment from Hope Medicine, and a clinical trial collaboration with MSD. Financially, BioInvent strengthened its position through a directed share issue of approximately SEK 300 million, ending the year with SEK 1.6 billion in liquid funds and investments. On the sustainability front, the company aligned its operations with six UN Sustainable Development Goals, maintained a low sick leave rate of 2.2%, and established an independent whistleblowing function.
Company: BioInvent International AB
Sector: Health Care
Country: Sweden
Year: 2022
Type: AR2
Pages: 92
Back to company
BioInvent International AB
Annual Report
The report highlights BioInvent's progress in 2022, during which the company expanded its clinical pipeline to five projects in ongoing clinical development. Key achievements included a new exclusive option and license agreement with Exelixis, a milestone payment from Hope Medicine, and a clinical trial collaboration with MSD. Financially, BioInvent strengthened its position through a directed share issue of approximately SEK 300 million, ending the year with SEK 1.6 billion in liquid funds and investments. On the sustainability front, the company aligned its operations with six UN Sustainable Development Goals, maintained a low sick leave rate of 2.2%, and established an independent whistleblowing function.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees